Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

Thanks RJFL, I see the 200 mg/kg mouse doses on CTIX web site, and now looking back at the Kumar 2012 AACR poster, that in A549 lung carcinoma studies, 50 mg/kg Kevetrin was indistinguishable from controls, 100 mg/kg was better, 200 mg/kg better, and 2 cycles of 200 mg/kg best at delaying tumor growth.

I'm not really sure how to best scale these doses to humans, but scaling based on BSA seems like a good start. Of course the PK/PD differences between mice and humans matter greatly too. I'm sure the CTIX scientists have their models.

There was a nice point / counterpoint discussion of using BSA to dose cancer drugs (more for individual human dosage, not prediction of HED based on preclinical work):

http://www.nature.com/clpt/journal/v95/n4/abs/clpt201412a.html

http://www.nature.com/clpt/journal/v95/n4/abs/clpt20147a.html

"The historical rationale for using BSA-based dosing was to provide an allometric parameter for scaling dose determined in animals to humans, but that is not a sufficient argument to justify its use. Indeed, scaling has been used to determine the first level of dose of the first-in-human phase I study (usually 1/10 of the Lethal Dose 10)"

So if scaling animal to human BSA is not a good model for estimating efficacy equivalence (but only for starting dose), what is a better model?

I guess just use the animal data to estimate a safe starting point, then use the clinical trial data to determine efficacy and safety data? Maybe there are just too many variables for the simple BSA scaling to be useful, but I'd like to know what is a better general model.

Interesting idea about brilacidin for surgical prophylaxis. I work in the OR during many neurosurgical procedures, and IV antibiotics are usually given by the anesthesiologist / nurse anesthetist at the start of the case. I haven't seen powder form being used much. One of the orthopedic spine surgeons uses lots of antibiotic irrigation before closing, and has low infection rates, so maybe local wound application is a good idea in addition to systemic administration. While brilacidin resistance is less likely than for other antibiotics, I wonder if they will save the "good stuff" for the resistant cases? I would guess people would hold off on brilacidin use (just like they do now for daptomycin) for the vancomycin and methicillin resistant bacteria.